"Biological Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Treatment of diseases with biological materials or biological response modifiers, such as the use of GENES; CELLS; TISSUES; organs; SERUM; VACCINES; and humoral agents.
| Descriptor ID |
D001691
|
| MeSH Number(s) |
E02.095
|
| Concept/Terms |
Biological Therapy- Biological Therapy
- Biological Therapies
- Therapies, Biological
- Therapy, Biological
- Biologic Therapy
- Biologic Therapies
- Therapies, Biologic
- Therapy, Biologic
- Biotherapy
- Biotherapies
|
Below are MeSH descriptors whose meaning is more general than "Biological Therapy".
Below are MeSH descriptors whose meaning is more specific than "Biological Therapy".
This graph shows the total number of publications written about "Biological Therapy" by people in this website by year, and whether "Biological Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 2 | 4 |
| 2005 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 3 | 0 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 3 | 0 | 3 |
| 2018 | 1 | 2 | 3 |
| 2019 | 0 | 2 | 2 |
| 2020 | 3 | 1 | 4 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biological Therapy" by people in Profiles.
-
Early Intestinal Ultrasound Response to Biologic Therapy Predicts Endoscopic Remission in Children with Ileal Crohn's Disease: Results from the Prospective Super Sonic Study. J Crohns Colitis. 2024 Aug 06; 18(7):1002-1011.
-
Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD. BMC Gastroenterol. 2022 Feb 19; 22(1):71.
-
Early vs Late Use of Anti-TNFa Therapy in Adult Patients With Crohn Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis. 2020 11 19; 26(12):1808-1818.
-
Emerging treatment options for extraintestinal manifestations in IBD. Gut. 2021 04; 70(4):796-802.
-
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy. J Eur Acad Dermatol Venereol. 2020 Dec; 34(12):e770-e772.
-
Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. J Eur Acad Dermatol Venereol. 2020 Dec; 34(12):2830-2838.
-
Perspectives of Clinicians in the United States and Europe on Monitoring Levels of Biologic Agents in Patients Receiving Biologic Therapies for Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 08; 17(9):1718-1723.
-
Too Soon to Discard 5-ASAs? Am J Gastroenterol. 2019 03; 114(3):534-535.
-
Uncharted Waters: Challenges in the Era of Biologic Therapies for Nasal Polyposis. J Allergy Clin Immunol Pract. 2019 01; 7(1):68-70.
-
Biologics for the primary care physician: Review and treatment of psoriasis. Dis Mon. 2019 Mar; 65(3):51-90.